Does Cosentyx Affect COVID-19 Vaccine Efficacy?
No direct clinical trials assess Cosentyx (secukinumab, an IL-17 inhibitor for psoriasis and arthritis) on COVID-19 vaccine efficacy. Observational data show no clear reduction in antibody responses. A 2022 study of 965 patients on biologics, including secukinumab, found seroconversion rates after mRNA vaccines comparable to healthy controls (94% vs. 99%), with secukinumab users achieving 96% seropositivity.[1] Neutralizing antibody levels were similar across groups.[1]
What About Other Vaccines with Cosentyx?
Limited evidence for non-COVID vaccines. Secukinumab does not broadly impair immune responses; it targets IL-17, sparing humoral immunity key to most vaccines. Post-marketing data report normal responses to influenza and pneumococcal vaccines in Cosentyx users.[2] Guidelines from the National Psoriasis Foundation recommend vaccination without pausing therapy.[3]
How Does Cosentyx Work and Why Might It Matter?
Cosentyx blocks IL-17A, reducing inflammation in autoimmune conditions. Unlike broad immunosuppressants (e.g., JAK inhibitors or rituximab), it minimally affects B-cell antibody production or T-cell memory, preserving vaccine-induced protection.[4] Real-world studies confirm this selectivity.[1][5]
Risk of Breakthrough Infections?
Patients on Cosentyx had COVID-19 hospitalization rates similar to non-biologic psoriasis patients (1.5% vs. 1.8%) in a 2023 analysis of over 5,000 cases.[6] No increased severe outcomes linked to reduced vaccine efficacy. Boosters elicit robust responses.[1]
Guidelines for Vaccination on Cosentyx?
ACR and EULAR advise continuing biologics like secentyx during vaccination. Pause only if active infection; vaccinate before starting therapy if possible.[7][8] Live vaccines are contraindicated, but COVID-19 shots are inactivated/mRNA.
Compared to Other Biologics?
| Biologic | Vaccine Impact | Notes |
|----------|---------------|-------|
| Secukinumab (Cosentyx) | Minimal | High seroconversion[1] |
| Adalimumab (Humira) | Minimal | Similar antibodies[5] |
| Dupilumab (Dupixent) | Minimal | No difference[1] |
| Rituximab | Significant reduction | B-cell depletion[4] |
| Baricitinib (JAKi) | Moderate reduction | T-cell effects[9] |
Cosentyx fares better than lymphocyte-depleting agents.
Sources
[1]: JAMA Dermatology - Biologics and mRNA Vaccine Response
[2]: Novartis Cosentyx Prescribing Info
[3]: National Psoriasis Foundation Guidelines
[4]: Nature Reviews Rheumatology - Immunomodulators and Vaccines
[5]: British Journal of Dermatology - Psoriasis Biologics Study
[6]: JAMA Network Open - COVID Outcomes in Biologics
[7]: ACR COVID-19 Guidelines
[8]: EULAR Vaccine Recommendations
[9]: Annals of Rheumatic Diseases - JAKi and Vaccines